PACLITAXEL ELUTING PTA BALLOON CATHETER (OTW) Latest generation paclitaxel-eluting balloon for peripheral interventions Designed for below the knee interventions PACLITAXEL ELUTING PTA BALLOON CATHETER (OTW) Latest generation paclitaxel-eluting balloon for peripheral interventions Ordering Information Balloon length (mm) BioPath™ 014 offers excellent pushability, trackability and crossability due to a low balloon profile, low tip entry profile and a hydrophilic coating on the distal shaft of the catheter. BioPath 014, with its unique shellac coating, delivers the designated paclitaxel dosage where it matters most – across the target lesion. L: 120 cm usable catheter length XL: 150 cm usable catheter length BioPath 014 is indicated for: > De-novo lesions > Pre- and post-dilatation in case of peripheral stent implantation 1. Axel D.L. et al. Circulation 1997; 96:636-45 2. A. Posa et al. Catheterization and Cardiovascular Interventions 76:395–403 (2010) 3. Data on file BioPath™ 014 paclitaxel-eluting balloon catheter is CE Mark approved. CAUTION: ﬔe law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. BioPath is a trademark or registered trademark of Biosensors International Group, Ltd. All cited trademarks are the property of their respective owners. Les informations relatives à ce produit ne sont pas destinées aux professionnels de santé exerçant en France – Any information related to this product is not intended for health care professionals who practice in France. Not available for sale in the United States and certain other countries. © 2013 Biosensors International Group, Ltd. All rights reserved. BIOSENSORS INTERVENTIONAL TECHNOLOGIES PTE LTD > Restenosis after realisation of b

ﬔe right choice Delivering the paclitaxel drug ﬔe treatment process Immediately after the controlled PTA, injury to the vessel wall key pathways contribute to the formation of neointimal hyperplasia. Injury from cracking plaque can lead to narrowing of the lumen. ﬔe paclitaxel dose will act over the short term to inhibit cell re-growth. ﬔe BioPath 014 balloon coating ™ With balloon dilatation, the injuries to the arterial wall initiate an inflammatory reaction with an excretion of growth factors which trigger the onset of cell division and smooth muscle cell migration. ﬔe BioPath 014 balloon coating...